Total Payments
$124,195
2024 Payments
$38,211
Companies
43
Transactions
931
Medicare Patients
3,793
Medicare Billing
$1.3M
Payment Breakdown by Category
Other$89,444 (72.0%)
Food & Beverage$18,316 (14.7%)
Consulting$13,274 (10.7%)
Travel$3,072 (2.5%)
Education$89.21 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $85,815 | 35 | 69.1% |
| Food and Beverage | $18,316 | 867 | 14.7% |
| Consulting Fee | $13,274 | 7 | 10.7% |
| Honoraria | $3,600 | 1 | 2.9% |
| Travel and Lodging | $3,072 | 15 | 2.5% |
| Education | $89.21 | 4 | 0.1% |
| Debt forgiveness | $29.57 | 2 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $43,028 | 204 | $0 (2024) |
| PFIZER INC. | $38,331 | 76 | $0 (2023) |
| Janssen Biotech, Inc. | $9,061 | 124 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $8,763 | 6 | $0 (2021) |
| GENZYME CORPORATION | $6,747 | 32 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $6,525 | 12 | $0 (2024) |
| Phathom Pharmaceuticals, Inc. | $2,541 | 8 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $1,338 | 78 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,243 | 80 | $0 (2024) |
| AIMMUNE THERAPEUTICS, INC. | $958.08 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $38,211 | 156 | ABBVIE INC. ($12,596) |
| 2023 | $16,358 | 130 | ABBVIE INC. ($14,400) |
| 2022 | $15,263 | 95 | ABBVIE INC. ($14,348) |
| 2021 | $12,085 | 84 | E.R. Squibb & Sons, L.L.C. ($8,763) |
| 2020 | $6,462 | 33 | PFIZER INC. ($5,969) |
| 2019 | $20,980 | 159 | PFIZER INC. ($19,508) |
| 2018 | $12,895 | 146 | PFIZER INC. ($10,801) |
| 2017 | $1,939 | 128 | AbbVie, Inc. ($442.14) |
All Payment Transactions
931 individual payment records from CMS Open Payments — Page 1 of 38
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/27/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $10.03 | General |
| Category: Immunology | ||||||
| 12/22/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $17.03 | General |
| Category: Immunology | ||||||
| 12/20/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $16.55 | General |
| Category: LIVER DISEASE | ||||||
| 12/12/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $3.46 | General |
| Category: Immunology | ||||||
| 12/11/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $23.68 | General |
| Category: Immunology | ||||||
| 12/11/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $7.18 | General |
| Category: VIROLOGY | ||||||
| 12/09/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,933.00 | General |
| Category: Immunology | ||||||
| 12/09/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $78.58 | General |
| Category: Immunology | ||||||
| 12/09/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Travel and Lodging | Cash or cash equivalent | $71.40 | General |
| Category: Immunology | ||||||
| 12/09/2024 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $12.87 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/09/2024 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $0.80 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/05/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,325.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/04/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Food and Beverage | In-kind items and services | $18.92 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/02/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $22.01 | General |
| Category: Immunology | ||||||
| 11/27/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $22.30 | General |
| Category: Gastroenterology | ||||||
| 11/27/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $9.00 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/25/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $13.24 | General |
| Category: IMMUNOLOGY | ||||||
| 11/22/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $13.84 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 11/21/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $17.77 | General |
| Category: LIVER DISEASE | ||||||
| 11/19/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $13.48 | General |
| Category: LIVER DISEASE | ||||||
| 11/18/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $21.85 | General |
| Category: Immunology | ||||||
| 11/16/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,128.00 | General |
| Category: Immunology | ||||||
| 11/15/2024 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $14.24 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/15/2024 | ABBVIE INC. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $0.92 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/14/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Food and Beverage | In-kind items and services | $98.31 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 22 | 969 | 17,093 | $1.5M | $388,570 |
| 2022 | 21 | 944 | 16,465 | $1.4M | $385,018 |
| 2021 | 21 | 1,039 | 11,186 | $1.3M | $300,092 |
| 2020 | 25 | 841 | 7,100 | $893,833 | $212,959 |
Total Patients
3,793
Total Services
51,844
Medicare Billing
$1.3M
Procedure Codes
90
All Medicare Procedures & Services
90 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J3380 | Injection, vedolizumab, 1 mg | Office | 2023 | 39 | 14,100 | $561,000 | $244,030 | 43.5% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 23 | 2,020 | $282,800 | $53,524 | 18.9% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 135 | 136 | $166,736 | $25,813 | 15.5% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 62 | 62 | $56,073 | $9,624 | 17.2% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 111 | 111 | $126,355 | $9,276 | 7.3% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 87 | 87 | $82,285 | $5,839 | 7.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 58 | 58 | $19,082 | $5,560 | 29.1% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 57 | 59 | $43,260 | $4,210 | 9.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 43 | 51 | $15,555 | $4,177 | 26.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 50 | 71 | $12,911 | $4,098 | 31.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 60 | 65 | $13,910 | $3,589 | 25.8% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 21 | 22 | $20,042 | $3,359 | 16.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 25 | 30 | $9,990 | $2,807 | 28.1% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 24 | 24 | $20,667 | $2,683 | 13.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 24 | 24 | $9,432 | $2,430 | 25.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 41 | 49 | $11,221 | $2,261 | 20.1% |
| 91010 | Study of esophagus to assess movement | Office | 2023 | 11 | 11 | $5,775 | $1,786 | 30.9% |
| 91037 | Monitoring and recording of esophageal function through nasal tube with electrode | Office | 2023 | 11 | 11 | $4,675 | $1,360 | 29.1% |
| 43450 | Dilation of esophagus | Facility | 2023 | 46 | 46 | $22,851 | $1,304 | 5.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 11 | 11 | $1,452 | $318.65 | 21.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 19 | 33 | $429.00 | $277.20 | 64.6% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 11 | 12 | $1,704 | $245.76 | 14.4% |
| J3380 | Injection, vedolizumab, 1 mg | Office | 2022 | 34 | 12,900 | $490,200 | $223,672 | 45.6% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2022 | 29 | 2,600 | $364,000 | $74,011 | 20.3% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 117 | 117 | $142,404 | $21,840 | 15.3% |
About Dr. Benjamin Hall, MD
Dr. Benjamin Hall, MD is a Gastroenterology healthcare provider based in Omaha, Nebraska. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/21/2008. The National Provider Identifier (NPI) number assigned to this provider is 1851556724.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Benjamin Hall, MD has received a total of $124,195 in payments from pharmaceutical and medical device companies, with $38,211 received in 2024. These payments were reported across 931 transactions from 43 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($85,815).
As a Medicare-enrolled provider, Hall has provided services to 3,793 Medicare beneficiaries, totaling 51,844 services with total Medicare billing of $1.3M. Data is available for 4 years (2020–2023), covering 90 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Omaha, NE
- Active Since 07/21/2008
- Last Updated 10/28/2016
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1851556724
Products in Payments
- XELJANZ (Drug) $38,289
- RINVOQ (Biological) $35,306
- DUPIXENT (Biological) $9,291
- ZEPOSIA (Drug) $8,677
- TREMFYA (Drug) $6,649
- SKYRIZI (Biological) $2,961
- HUMIRA (Biological) $2,889
- STELARA (Biological) $2,688
- VOQUEZNA (Drug) $2,541
- XIFAXAN (Drug) $1,129
- ZENPEP (Drug) $793.56
- Entyvio (Biological) $650.59
- ENTYVIO (Biological) $519.87
- Humira (Biological) $473.76
- IBSRELA (Drug) $360.92
- CREON (Drug) $319.70
- LINZESS (Drug) $318.71
- Trulance (Drug) $301.84
- Mavyret (Drug) $297.97
- OCALIVA (Drug) $267.33
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Omaha
Rowen Zetterman, Md, MD
Gastroenterology — Payments: $150,426
Gastroenterology $150,426
Sandeep Mukherjee, Md, MD
Gastroenterology — Payments: $146,207
Gastroenterology $146,207
Peter Mannon, M.d, M.D
Gastroenterology — Payments: $110,607
Gastroenterology $110,607
Dr. Kimberly Harmon, Md, MD
Gastroenterology — Payments: $35,200
Gastroenterology $35,200
Dr. Grant Hutchins, Md, MD
Gastroenterology — Payments: $17,175
Gastroenterology $17,175
Dr. Trevor Pearson, Md, MD
Gastroenterology — Payments: $13,509
Gastroenterology $13,509